Cargando…

Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients

BACKGROUND: Cryopreservation of ovarian tissue is a fertility-preservation option for women before gonadotoxic treatments. However, cryopreserved ovarian tissue transplantation must be performed with caution in women with malignancies that may metastasize to the ovaries. For this purpose, detecting...

Descripción completa

Detalles Bibliográficos
Autores principales: Zver, Tristan, Frontczak, Sophie, Poirot, Catherine, Rives-Feraille, Aurélie, Leroy-Martin, Brigitte, Koscinski, Isabelle, Arbez-Gindre, Francine, Garnache-Ottou, Francine, Roux, Christophe, Amiot, Clotilde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767661/
https://www.ncbi.nlm.nih.gov/pubmed/35042558
http://dx.doi.org/10.1186/s13048-021-00936-4
_version_ 1784634780882567168
author Zver, Tristan
Frontczak, Sophie
Poirot, Catherine
Rives-Feraille, Aurélie
Leroy-Martin, Brigitte
Koscinski, Isabelle
Arbez-Gindre, Francine
Garnache-Ottou, Francine
Roux, Christophe
Amiot, Clotilde
author_facet Zver, Tristan
Frontczak, Sophie
Poirot, Catherine
Rives-Feraille, Aurélie
Leroy-Martin, Brigitte
Koscinski, Isabelle
Arbez-Gindre, Francine
Garnache-Ottou, Francine
Roux, Christophe
Amiot, Clotilde
author_sort Zver, Tristan
collection PubMed
description BACKGROUND: Cryopreservation of ovarian tissue is a fertility-preservation option for women before gonadotoxic treatments. However, cryopreserved ovarian tissue transplantation must be performed with caution in women with malignancies that may metastasize to the ovaries. For this purpose, detecting minimal residual disease (MRD) in the ovarian cortex using sensitive methods is a crucial step. We developed an automated ovarian tissue dissociation method to obtain ovarian cell suspensions. RESULTS: We assessed MRD by multicolor flow cytometry (MFC) in cryopreserved ovarian cortex of 15 leukemia patients: 6 with B-cell acute lymphoblastic leukemia (B-ALL), 2 with T-cell acute lymphoblastic leukemia (T-ALL) and 7 with acute myeloid leukemia (AML). Ovarian MRD was positive in 5 of the 15 leukemia patients (one T-ALL and 4 AML). No B-ALL patient was positive by MFC. Quantitative reverse-transcribed polymerase chain reaction was performed when a molecular marker was available, and confirmed the MFC results for 3 patients tested. Xenografts into immunodeficient mice were also performed with ovarian cortical tissue from 10 leukemia patients, with no evidence of leukemic cells after the 6-month grafting period. CONCLUSIONS: In conclusion, this is the first study using MFC to detect MRD in ovarian cortical tissue from acute leukemia patients. MFC has been accepted in clinical practice for its ease of use, the large number of parameters available simultaneously, and high throughput analysis. We demonstrate here that MFC is a reliable method to detect MRD in cryopreserved ovarian tissue, with a view to controlling the oncological risk before ovarian tissue transplantation in leukemia patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-021-00936-4.
format Online
Article
Text
id pubmed-8767661
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87676612022-01-19 Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients Zver, Tristan Frontczak, Sophie Poirot, Catherine Rives-Feraille, Aurélie Leroy-Martin, Brigitte Koscinski, Isabelle Arbez-Gindre, Francine Garnache-Ottou, Francine Roux, Christophe Amiot, Clotilde J Ovarian Res Research BACKGROUND: Cryopreservation of ovarian tissue is a fertility-preservation option for women before gonadotoxic treatments. However, cryopreserved ovarian tissue transplantation must be performed with caution in women with malignancies that may metastasize to the ovaries. For this purpose, detecting minimal residual disease (MRD) in the ovarian cortex using sensitive methods is a crucial step. We developed an automated ovarian tissue dissociation method to obtain ovarian cell suspensions. RESULTS: We assessed MRD by multicolor flow cytometry (MFC) in cryopreserved ovarian cortex of 15 leukemia patients: 6 with B-cell acute lymphoblastic leukemia (B-ALL), 2 with T-cell acute lymphoblastic leukemia (T-ALL) and 7 with acute myeloid leukemia (AML). Ovarian MRD was positive in 5 of the 15 leukemia patients (one T-ALL and 4 AML). No B-ALL patient was positive by MFC. Quantitative reverse-transcribed polymerase chain reaction was performed when a molecular marker was available, and confirmed the MFC results for 3 patients tested. Xenografts into immunodeficient mice were also performed with ovarian cortical tissue from 10 leukemia patients, with no evidence of leukemic cells after the 6-month grafting period. CONCLUSIONS: In conclusion, this is the first study using MFC to detect MRD in ovarian cortical tissue from acute leukemia patients. MFC has been accepted in clinical practice for its ease of use, the large number of parameters available simultaneously, and high throughput analysis. We demonstrate here that MFC is a reliable method to detect MRD in cryopreserved ovarian tissue, with a view to controlling the oncological risk before ovarian tissue transplantation in leukemia patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-021-00936-4. BioMed Central 2022-01-18 /pmc/articles/PMC8767661/ /pubmed/35042558 http://dx.doi.org/10.1186/s13048-021-00936-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zver, Tristan
Frontczak, Sophie
Poirot, Catherine
Rives-Feraille, Aurélie
Leroy-Martin, Brigitte
Koscinski, Isabelle
Arbez-Gindre, Francine
Garnache-Ottou, Francine
Roux, Christophe
Amiot, Clotilde
Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients
title Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients
title_full Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients
title_fullStr Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients
title_full_unstemmed Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients
title_short Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients
title_sort minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767661/
https://www.ncbi.nlm.nih.gov/pubmed/35042558
http://dx.doi.org/10.1186/s13048-021-00936-4
work_keys_str_mv AT zvertristan minimalresidualdiseasedetectionbymulticolorflowcytometryincryopreservedovariantissuefromleukemiapatients
AT frontczaksophie minimalresidualdiseasedetectionbymulticolorflowcytometryincryopreservedovariantissuefromleukemiapatients
AT poirotcatherine minimalresidualdiseasedetectionbymulticolorflowcytometryincryopreservedovariantissuefromleukemiapatients
AT rivesferailleaurelie minimalresidualdiseasedetectionbymulticolorflowcytometryincryopreservedovariantissuefromleukemiapatients
AT leroymartinbrigitte minimalresidualdiseasedetectionbymulticolorflowcytometryincryopreservedovariantissuefromleukemiapatients
AT koscinskiisabelle minimalresidualdiseasedetectionbymulticolorflowcytometryincryopreservedovariantissuefromleukemiapatients
AT arbezgindrefrancine minimalresidualdiseasedetectionbymulticolorflowcytometryincryopreservedovariantissuefromleukemiapatients
AT garnacheottoufrancine minimalresidualdiseasedetectionbymulticolorflowcytometryincryopreservedovariantissuefromleukemiapatients
AT rouxchristophe minimalresidualdiseasedetectionbymulticolorflowcytometryincryopreservedovariantissuefromleukemiapatients
AT amiotclotilde minimalresidualdiseasedetectionbymulticolorflowcytometryincryopreservedovariantissuefromleukemiapatients